Member Info for unknownquantity

Very encouraging news from the latest RNS today:

"The acquisition serves to accelerate the Group's US expansion plans, providing a footprint and an opportunity to add further scale. The Directors believe that, based on relative population sizes, the US represents an addressable market around five times larger than the UK, and therefore believe the acquisition represents a significant milestone in its growth strategy... Checkit is also pleased to announce the appointment of two senior business development executives, Kit Kyte and Steve Peck, effective 1 February 2021... Kit Kyte... was previously with New York headquartered Genpact, a global professional services firm delivering digital transformation by putting digital and data to work to create competitive advantage... Steve Peck ... was previously employed by Oracle NetSuite, the world's number 1 cloud business management software suite. Steve has considerable experience of Checkit's two most important vertical markets, Healthcare and Food Retail."

I've held this stock from the Electron days and will continue to do so. Why? Once everyone realises the potential of using the sensors and workflow to support adaptation and mitigation to climate change, the agriculture and food market alone will be enormous (accounts for around 24% of all GHG emissions globally). Furthermore, the upfront costs associated with using the sensors/software are relatively low compared to other adaptation/mitigation methods.

Just imagine if the sensors run off RE from IKA batteries in the future?

DYOR
UQ

Have a look again at the RNS:

IPF is characterised by excessive deposition and remodelling of extracellular matrix (ECM), leading to lung scarring and loss of respiratory function. Over-production of key ECM components are a key driver in IPF progression:
· NXP004 showed a dose-dependent reduction in the secretion of several key ECM components
· These data suggest NXP004 compares favourably to current standard of care with regard to anti-fibrotic activity in this model
· Delivery of a full pre-clinical study data set in multiple human IPF tissue samples is the next focus

Now have a look at a study in May 2020 on the links between IPF symptoms and those of COVID-19:

The symptoms associated with COVID-19 are diverse, ranging from mild upper respiratory tract symptoms to severe acute respiratory distress syndrome. The major risk factors for severe COVID-19 are shared with idiopathic pulmonary fibrosis (IPF).... However, the role of antifibrotic therapy in patients with IPF who contract SARS-CoV-2 infection, and the scientific rationale for their continuation or cessation, is poorly defined. Furthermore, several licensed and potential antifibrotic compounds have been assessed in models of acute lung injury and viral pneumonia. Data from previous coronavirus infections such as severe acute respiratory syndrome and Middle East respiratory syndrome, as well as emerging data from the COVID-19 pandemic, suggest there could be substantial fibrotic consequences following SARS-CoV-2 infection. Antifibrotic therapies that are available or in development could have value in preventing severe COVID-19 in patients with IPF, have the potential to treat severe COVID-19 in patients without IPF, and might have a role in preventing fibrosis after SARS-CoV-2 infection.

Source: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30225-3/fulltext

Sounds to me we are about to see a new name entering the scene to (fast track) the treatment for severe COVID-19 and IPF symptoms. Hold on! Dyor. This is as exciting as CKT and IKA.

UQ

https://fuelcellsworks.com/news/cities-and-regions-support-ambitious-eu-hydrogen-strategy/

Maybe the share price increase in a company like PPS and ITM has something to do with Germany's strong commitment to H2. According to my research a company that has hydrogen applications for buses, commercial vehicles, ships and stationary power generation plus a base outside Munich is also ready for major expansion... DYOR

https://www.reuters.com/article/us-health-coronavirus-germany-stimulus/germany-earmarks-10-billion-for-hydrogen-expansion-idUSKBN23B10L

I've seen in this chat that there may be research into developing medical masks incorporating graphene properties, but has anyone any knowledge/experience in the development of medical gowns using graphene? Given graphene can be used to make medical gowns anti-bacterial, elastic, light and easy to sanitise for reuse (i.e. clean at over 130C as practiced by hospitals), graphene-based medical-wear could be exactly what we need to protect hospital staff and carers who depend heavily on imported single-use incinerated versions? Anyone any views, or spoken to VRS on this? The potential is unthinkable and a win-win for everyone...

"The company's new hydrogen-fuelled EV charger is the focus of our business for the remainder of this year and will set the benchmark for sustainable, off-grid and reliable power supply to an industry whose size is estimated to be near £100bn in the UK alone.”

Climate variability and change is already with us. Think again about the market value for clean energy and sustainable agriculture (energy production and agro-industry account for 50% of all GHG emissions). Does AFC technology meet the former? If so what will be the market value for this type of technology be in the next decade? It can only... increase.